GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » Market Cap

Avidity Biosciences (Avidity Biosciences) Market Cap : $1,941.97 Mil (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Avidity Biosciences's share price for the quarter that ended in Dec. 2023 was $9.05. Avidity Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 79.28 Mil. Therefore, Avidity Biosciences's market cap for the quarter that ended in Dec. 2023 was $717.44 Mil.

Avidity Biosciences's quarterly market cap declined from Jun. 2023 ($821.44 Mil) to Sep. 2023 ($472.77 Mil) but then increased from Sep. 2023 ($472.77 Mil) to Dec. 2023 ($717.44 Mil).

Avidity Biosciences's annual market cap increased from Dec. 2021 ($1,135.11 Mil) to Dec. 2022 ($1,548.15 Mil) but then declined from Dec. 2022 ($1,548.15 Mil) to Dec. 2023 ($717.44 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Avidity Biosciences's Enterprise Value for Today is $1,356.47 Mil.


Avidity Biosciences Market Cap Historical Data

The historical data trend for Avidity Biosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences Market Cap Chart

Avidity Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 958.76 1,135.11 1,548.15 717.44

Avidity Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,548.15 1,086.98 821.44 472.77 717.44

Competitive Comparison of Avidity Biosciences's Market Cap

For the Biotechnology subindustry, Avidity Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avidity Biosciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avidity Biosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Avidity Biosciences's Market Cap falls into.



Avidity Biosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Avidity Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$9.05*79.275
=$717.44

Avidity Biosciences's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$9.05*79.275
=$717.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avidity Biosciences  (NAS:RNA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Avidity Biosciences Market Cap Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Avidity Biosciences (Avidity Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Executives
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
W. Michael Flanagan officer: Chief Technical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Teresa Mccarthy officer: Chief Human Resources Officer 10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Arthur A Levin officer: Chief Scientific Officer 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Sarah Boyce director, officer: President and CEO C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker director C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim officer: Chief Medical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Noreen Henig director C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Michael B. Martin director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037

Avidity Biosciences (Avidity Biosciences) Headlines